ライフサイエンスコーパス: combined therapy

1 conjugated estrogen; r = -0.507, P=0.004 for combined therapy).

2 Lactococcus lactis as tolerogenic adjuvant (combined therapy).

3 ation, which were further enhanced following combined therapy.

4 treated at some point with either single or combined therapy.

5 rlie acquired resistance to BRAFi and to the combined therapy.

6 lease of cargoes to achieve multi-functional combined therapy.

7 moral tissue was still intact 24 h after the combined therapy.

8 utcome was to assess the long-term safety of combined therapy.

9 he realistic application of phage-antibiotic combined therapy.

10 im analysis revealed significant benefit for combined therapy.

11 herapy for stable or responding patients was combined therapy.

12 CGT level in tumors subjected to CGT-NP+UTMD combined therapy.

13 otic and autophagy activities induced by the combined therapy.

14 s of contextualization, optimal arousal, and combined therapy.

15 ventricular size and function in response to combined therapy.

16 tion abrogated the therapeutic effect of the combined therapy.

17 ich PAKs mediate resistance to BRAFi and the combined therapy.

18 sify therapy, switch to another drug, or use combined therapy.

19 tial clinical and immunologic effects of the combined therapies.

20 of tamoxifen response and personalisation of combined therapies.

21 , it was less common in the groups receiving combined therapy (34/130 [26%]) than in the group treate

22 ng: tracer-determined glucose disposal rate (combined therapy, 52.4 +/- 2.9 mg x kg(-1) x min(-1), vs

23 te grade 3 mucositis was more prevalent with combined therapy, 84% v 43% (P <.001), resulting in a hi

24 lone, as compared with patients who received combined therapy (95 percent confidence interval, 1.10 t

25 In this context, antifungal combined therapy (ACT) has become an emerging strategy a

26 of renal interstitial fibrosis; therefore, a combined therapy aimed at simultaneously targeting multi

27 alysis of pulmonary metastases revealed that combined therapy also had a more potent antimetastatic e

28 Combined therapy also increases tumor destruction over e

29 Combined therapy also resulted in improved local control

30 The combined therapy also synergistically inhibited the accu

31 2.4 +/- 0.4 (standard error of the mean) for combined therapy and 0.9 +/- 0.2 for RF ablation alone (

32 was 49.0 months among patients treated with combined therapy and 29.3 months among those treated wit

33 On other measures the combined therapy and its 2 component therapies produced

34 o significant differences were found between combined therapy and ligation in rebleeding (29% vs. 30%

35 cterize pathophysiological changes following combined therapy and to determine whether radioresponse

36 nal patients (69) were treated with the same combined therapy and were analyzed.

37 increases in the immune responses (from the combined therapy) and duration of antibody response that

38 , 1 patient died suddenly while treated with combined therapy, and 1 patient died of unrelated causes

39 nts had resuscitated cardiac arrest while on combined therapy, and 1 patient had repeated, appropriat

40 i67 proliferation index were documented with combined therapy, and EGFR down-regulation was observed

41 jor treatments were no therapy, monotherapy, combined therapy, and potent antiretroviral therapy, res

42 eing treated with methotrexate-sulfasalazine combined therapy, and two of the patients were being tre

43 beta-blocker therapy and continuous pacing, combined therapy appears to provide reasonable, long-ter

44 Combined therapy, as compared with liposomal doxorubicin

45 Additionally, the combined therapy attenuated the formation of plasminogen

46 This combined therapy attenuates in vivo expression of SPARC,

47 ow that treatment of C57BL/6 donor mice with combined therapy before the transplant protects the reci

48 many cancers, survival depends on aggressive combined therapies, but treatment comes at a price.

49 replicon particles (HPV16-VRP) and that this combined therapy can eradicate human papillomavirus 16 (

50 t demonstrates that orthodontic-regenerative combined therapy can resolve complex clinical problems a

51 Combined therapy caused a predictable fall in hemoglobin

52 noma of the prostate, but outcome using this combined therapy compared with RT alone is not known.

53 duced microvessel counts in the tumors given combined therapy compared with the tumors given either a

54 Furthermore, combined therapies consisting of thermal ablation and ad

55 diopathic long-QT syndrome were treated with combined therapy consisting of continuous cardiac pacing

56 Combined therapy cost $1633 more (P = .01).

57 Therefore, we determined whether combined therapy could normalize insulin action in the Z

58 oup as a whole; however, in 50% of patients, combined therapy decreased PVRI by 20% more than did iNO

59 Surprisingly, the animals treated with the combined therapy did not perform as well as postnatally-

60 deletion of CD20-bearing cells and that the combined therapy did not significantly impair establishe

61 Four patients who received combined therapy died as a direct result of the treatmen

62 , 250 microL; total dose, 0.5 mg) alone; (c) combined therapy (doxorubicin injection immediately foll

63 The combined therapy efficiently suppressed T-cell prolifera

64 reduced immunosuppression, whereas a FOLFIRI combined therapy enhanced immunosuppression.

65 The combined therapy enhanced these independent effects of e

66 Combined therapy facilitated T:B cooperativity and enabl

67 d dose (480 mg/m(2)), five patients received combined therapy first and carboplatin alone second, and

68 After receiving a combined therapy for 24 weeks, 43.66% patients showed an

69 yostatin-1 and rituximab could be a valuable combined therapy for B cell malignancies.

70 ssion and provide an insight for designing a combined therapy for cancer treatment.

71 gest that Bryo-1 plus IL-2 may be a valuable combined therapy for cancer treatment.

72 eaths from non-small-cell lung cancer in the combined therapy group (62 vs 31 deaths; 0.09%vs 0.05%;

73 ity (BCVA) improved from 0.73 to 0.53 in the combined therapy group (P < .001) and from 0.79 to 0.72

74 istically significant after 21 months in the combined therapy group and 15 months in the monotherapy

75 mothermia (p < 0.01) (although >40mmHg); the combined therapy group required more fluid boluses (p <

76 h the control group was only achieved in the combined therapy group.

77 the radiotherapy group and 77 percent in the combined-therapy group (P<0.001).

78 te of overall survival was 55 percent in the combined-therapy group and 34 percent in the hyperfracti

79 years were 67 percent among patients in the combined-therapy group and 40 percent among patients in

80 The median survival was 72.2 months in the combined-therapy group and 59.3 months in the monotherap

81 e occurred in 113 participants (3.6%) in the combined-therapy group and in 157 (5.0%) in the dual-pla

82 l (P=0.008) were significantly higher in the combined-therapy group at four years.

83 ciliter (0.87 mmol per liter) greater in the combined-therapy group than in the dual-placebo group, a

84 akness and dizziness were more common in the combined-therapy group than in the dual-placebo group, b

85 onal control was significantly higher in the combined-therapy group than in the group given radiother

86 ree survival was significantly longer in the combined-therapy group than in the radiotherapy group (h

87 In the combined-therapy group there were higher frequencies of

88 Those in the combined-therapy group who frequently recorded their foo

89 eiving radiotherapy plus short-term ADT (the combined-therapy group), as compared with 57% among pati

90 l and regional control was 82 percent in the combined-therapy group, as compared with 72 percent in t

91 ation for groups 1, 2, and 3 but not for the combined-therapy group.

92 uency of diarrhea and hepatic effects in the combined-therapy group.

93 or the second intracavitary procedure in the combined-therapy group.

94 ate of reversible hematologic effects in the combined-therapy group.

95 acute toxic effects also were greater in the combined therapy groups.

96 ere generally similar in the monotherapy and combined therapy groups.

97 ized freeze-dried bone (DFDB) grafting (BG), combined therapy (GTR + BG) and a DFDB-glycoprotein spon

98 However, for non-contained defects, combined therapy (GTR + BG) demonstrated clinically sign

99 96 women assigned to combined therapy had non-small-cell lung cancer compared

100 Use of combined therapy has been proposed, using a bone graft i

101 The value of combined therapy has not been clearly established.

102 Combined therapy, however, demonstrated both favorable e

103 Resistance to the combined therapy, however, is mediated by mechanisms ind

104 rt demonstrates orthodontic and regenerative combined therapy in a 49-year-old male whose right maxil

105 s to summarize our long-term experience with combined therapy in patients with long-QT syndrome.

106 These studies indicate a possible role for combined therapy in the treatment of GLD.

107 possibility that both agents can be used as combined therapy in the treatment of ischemic heart dise

108 and decreased during both lisinopril and the combined therapy in which it was not different from base

109 The combined therapy increased perfusion, motor function, an

110 Combined therapy increases the survival of patients who

111 In comparison with individual treatments, combined therapy (iNO + dipyridamole) did not augment pu

112 These data suggest that combined therapy is a promising strategy for prevention

113 utic responses are T-cell-dependent, because combined therapy is not efficacious in severe combined i

114 t of the widespread clinical impression that combined therapy is superior to psychotherapy alone for

115 al role played by PRP, BPBM, and GTR in this combined therapy is unclear and needs to be elucidated.

116 Further study of this form of combined therapy is warranted.

117 In experiment 2, use of combined therapy led to increased coagulation in all tis

118 Combined therapy lengthens the time required for treatme

119 At one year, subjects who received combined therapy lost a mean (+/-SD) of 12.1+/-9.8 kg, w

120 ng on a decision maker's willingness to pay, combined therapy may be cost-effective, particularly for

121 effective only as long as they are used, and combined therapy may be more effective than monotherapy.

122 Combined therapy may improve outcome relative to monothe

123 injected liposomal doxorubicin (n = 26), or combined therapy (n = 30) and were compared with control

124 solated bileaflet chordal cutting versus the combined therapy (n=7 each).

125 therapy plus antidepressant pharmacotherapy (combined therapy; n = 352).

126 Therefore, combined therapies of anti-CD154 antibodies plus donor-s

127 tudy, we present seven patients for whom the combined therapies of PP/IVIG were successful in reversi

128 pes or pulsed-HIFU exposure in addition to a combined therapy of (90)Y-B3 and taxol to enhance the sy

129 Combined therapy of alphabeta-TCR-CsA for 7 days resulte

130 s stages of prostate cancer cells and that a combined therapy of antiandrogens and anti-PI3K/Akt inhi

131 e increased to 5.98 (95% CI, 0.72-216.0) for combined therapy of atorvastatin, pravastatin, or simvas

132 A combined therapy of avasimibe plus an anti-PD-1 antibody

133 est that MiPs should be further explored for combined therapy of cardiac and skeletal muscles.

134 Clinically, combined therapy of cisplatin (CDDP) and metformin is an

135 Combined therapy of cisplatin and ATP11B-targeted siRNA

136 rpose of this study was to determine whether combined therapy of glutaraldehyde-polymerized bovine he

137 The combined therapy of NB-UV-B and afamelanotide appears to

138 Women who used a combined therapy of oestrogen with cyclic progestagen (e

139 Postmenopausal women who use combined therapy of oestrogen with cyclic progestagen on

140 mm +/- 0.9 (P: <.001) was observed with the combined therapy of PEI followed by RF.

141 icroL of ethanol infused over 1 minute); (c) combined therapy of PEI immediately followed by RF ablat

142 immediately followed by RF ablation; or (d) combined therapy of RF ablation immediately followed by

143 Moreover, combined therapy of RSpo1 and keratinocyte growth factor

144 BMP7 and LfcinB as individual treatments and combined therapy on bovine nucleus pulposus (NP) cells b

145 n are added to statin therapy, the effect of combined therapy on LDL cholesterol levels is additive.

146 The effect of combined therapy on PAI-1 [5.6 (2.3, 8.8) ng/mL] was sig

147 dothelium, leading to synergistic effects of combined therapy on tissue perfusion.

148 d for selecting patients for more aggressive combined therapies or enrollment into trials targeting E

149 of lifestyle-modification counseling (i.e., combined therapy); or sibutramine plus brief lifestyle-m

150 s was 5 degrees C lower for tumors receiving combined therapy (P < 0.01).

151 he first antimicrobial used or lowest MIC of combined therapy (P = 0.006).

152 change in PAI-1 during ramipril (P=0.011) or combined therapy (P=0.006) but not during estrogens (P=0

153 In cells that are resistant to the combined therapy, PAKs regulate JNK and beta-catenin pho

154 In the succeeding nonrandomized part, combined therapy produced a 5-year overall survival of 1

155 Model-predicted cellular responses to the combined therapy provide good agreement with experimenta

156 A FOLFOX combined therapy reduced immunosuppression, whereas a FO

157 Combined therapy required significantly more sessions to

158 Moreover, the CD4(+)/SOCS1-KIR combined therapy resulted in decreased leukocytic organ

159 In the subcutaneous tumor model, the combined therapy resulted in improved survival.

160 Combined therapy resulted in significantly longer period

161 Combined therapy results in modest 12-month improvement

162 five patients received carboplatin first and combined therapy second.

163 The combined therapy significantly improved antitumor activi

164 Combined therapy significantly increased overall surviva

165 This combined therapy significantly prolonged the life span o

166 but the response to iNO was not augmented by combined therapy (SOD + iNO).

167 As a consequence of this combined therapy, strains resistant only to rifampin wer

168 Finally, a triple-response combined therapy strategy is achieved by PEGylated BP na

169 Moreover, our combined therapy synergistically attenuates tumor growth

170 rotection during ALI opens possibilities for combined therapies targeted to this protein set.

171 Combined therapies targeting aberrant properties of LSC

172 Combined therapies targeting common and subtype-specific

173 neuroprotective activities, suggesting that combined therapies targeting distinct Ass42 epitopes can

174 Combined therapies targeting glucose metabolism and poly

175 nhibitors, by targeted ER degradation, or by combined therapy targeting both ER and growth factor sig

176 ic blood pressure was 6.2 mm Hg greater with combined therapy than with dual placebo.

177 te of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.

178 dentify new therapeutic targets, and lead to combined therapies that are effective against highly het

179 lenge current trial design paradigm that for combined therapy to be successful individual agents shou

180 The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be

181 ing the framework for clinical evaluation of combined therapy to improve patient outcome in MM.

182 s to lie in a multidimensional approach with combined therapy to manage both cancer cachexia and asth

183 preclinical data supporting the use of this combined therapy to overcome the limitations of standard

184 ify LDLR as a promising metabolic target for combined therapy, to limit PDAC progression and disease

185 t different sites and may help us to develop combined therapies using anti-AR and anti-VEGF-C compoun

186 Combined therapy using both sorafenib and MEAN enhanced

187 Our findings reveal the potential for combined therapy using optimized doses of Physcion and D

188 85% of patients (39 of 46) in group A given combined therapy versus 11% (5 of 46) receiving lamivudi

189 rred in 31% of patients (14 of 45) receiving combined therapy versus 6% (3 of 48) receiving lamivudin

190 No advantages were observed with combined therapy versus benznidazole monotherapy.

191 (10% had life-threatening toxic effects with combined therapy vs 2% in the RT only group).

192 years of follow-up the overall survival for combined therapy was 26% (95% confidence interval [CI],

193 The 6-month maintenance response rate for combined therapy was 57.1% for the PDSS (P=.04 vs CBT al

194 In the randomized study, combined therapy was compared with RT only (n = 62): 64

195 A and SAMe treatment prevented this fall and combined therapy was more effective on preserving GSH le

196 Combined therapy was more likely to produce clinically s

197 This combined therapy was not lymphocyte depleting and did no

198 Whereas combined therapy was not significantly more effective th

199 Twelve combined therapies were conducted in the 11 patients.

200 dge, and argue that significant progress for combined therapies will require a better understanding o

201 roaches as well as their potential to obtain combined therapies with desired drug release profiles.

202 b, adalimumab, certolizumab, vedolizumab, or combined therapies with placebo or an active agent for i

203 2139 once per week for 15 weeks, followed by combined therapy with 250 mg intravenous REP 2139 and 18

204 Additionally, combined therapy with a FAK inhibitor and the antiangiog

205 Combined therapy with abciximab and ticlopidine has a pr

206 14 trial, a dose-ranging angiographic study, combined therapy with abciximab plus reduced-dose tPA en

207 ffectively improve the treatment efficacy of combined therapy with ADT and vaccination.

208 ment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has b

209 Combined therapy with antibiotics and antirejection medi

210 We demonstrate that combined therapy with antigen-induced CD4 derived DN Tre

211 nscheduled DNA synthesis that was reduced by combined therapy with antireceptor antibody specific to

212 Additionally, the impact of combined therapy with aspirin and other COX inhibitors i

213 Importantly, combined therapy with bortezomib plus cisplatin induced

214 Combined therapy with both Src and PI3K/PKB inhibitors m

215 Although combined therapy with cyclophosphamide and glucocorticoi

216 Initial results indicate that combined therapy with etanercept plus methotrexate may b

217 Here we demonstrate that combined therapy with human GM-CSF and low-dose IL-2 is

218 tained with the combination, suggesting that combined therapy with IGF-1 and OP-1 may be an effective

219 vidence in this study strongly suggests that combined therapy with inhibitors of YAP (such as vertepo

220 o treatment demonstrates a possible role for combined therapy with iNO and PGI2 in infants with sever

221 c intermediates, we assessed the efficacy of combined therapy with lovastatin and cholesterol.

222 PTEN/PI3K pathway that would be amenable to combined therapy with MAPK pathway inhibitors for the tr

223 These results suggest that combined therapy with NSAIDs and antioxidants might be u

224 l was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or

225 Therefore, we evaluated whether combined therapy with paclitaxel and LY294002 would resu

226 patients with C4d positive AHR who received combined therapy with PPH and polyclonal rabbit antithym

227 ctivator (rtPA) makes it a candidate for the combined therapy with rtPA for the acute treatment of is

228 imus (3 mg/kg per day for 14 days); group 4, combined therapy with sirolimus and mCTLA-4Ig.

229 Combined therapy with these two agents very effectively

230 Combined therapy with thrombospondin-1 type I repeats (3

231 Combined therapy with warfarin and aspirin has been show

232 e compared the 3180 participants assigned to combined therapy (with rosuvastatin and the two antihype

233 Combined therapy yielded significantly greater lengths o